Inovio Pharma Q4 Loss Narrows - Quick Facts

(RTTNews) - Inovio Pharmaceuticals, Inc. (INO) reported fourth-quarter net loss attributable to stockholders of $7.4 million, or $0.12 per share, compared to a net loss of $15.5 million or $0.30 per share, prior year. The company said the improvement of $8.1 million in net loss attributable to common stockholders, resulted primarily from a reduction in non-cash accounting expense in 2014 related to the change in fair value of common stock warrants based on a required quarterly mark to market adjustment to reflect changes in the Company's stock price.

Total revenue was $2.5 million, compared to $1.7 million, last year.

Joseph Kim, President and CEO, said: "In 2015, we look forward to our first cancer data, our complete phase II data being published in a peer-reviewed medical journal, advancing the many steps toward our phase III launch, initiating clinical studies for additional diseases, and new corporate development steps. Our phase II data was a significant validation of the ideal characteristics we are pursuing with our active immunotherapy technology; and each day we continue to take the methodical steps necessary to realize the significant commercial and medical potential of our transformative applications and products."